Literature DB >> 22312449

Overview of screening methods for fatty liver disease in children.

Caroline Anitha Devadason1, Ann O Scheimann.   

Abstract

The prevalence of obesity and obesity related comorbidities including diabetes and nonalcoholic fatty liver disease (NAFLD) has been rising globally. Nonalcoholic fatty liver disease is emerging as a common liver disease among adults which can lead to the eventual development of complications including cirrhosis and hepatocellular carcinoma. With the rise of obesity in children, the development of detection methods for the presence of NAFLD is becoming imperative. Although the gold standard for diagnosis is liver biopsy, practical issues limit pediatric use and warrant development of noninvasive or minimally invasive screening tools for the detection and staging of NAFLD. A variety of diagnostic methods have been studied including use aminotransferases, imaging studies and serologic markers which have some population-based limitations. Additional factors such as gender and ethnicity may also play a role in the screening of NAFLD in pediatric population studies.

Entities:  

Keywords:  Alanine aminotransferase; Children; Detection methods; Ethnicity; Gender; Nonalcoholic fatty liver disease

Year:  2012        PMID: 22312449      PMCID: PMC3272075          DOI: 10.4254/wjh.v4.i1.1

Source DB:  PubMed          Journal:  World J Hepatol


  28 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

2.  The liver in obesity.

Authors:  S ZELMAN
Journal:  AMA Arch Intern Med       Date:  1952-08

3.  Decreased prevalence of nonalcoholic fatty liver disease in black obese children.

Authors:  Miriam V Louthan; Judy A Theriot; Ellen Zimmerman; John T Stutts; Craig J McClain
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-10       Impact factor: 2.839

4.  Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents.

Authors:  Jeffrey B Schwimmer; Nancy McGreal; Reena Deutsch; Milton J Finegold; Joel E Lavine
Journal:  Pediatrics       Date:  2005-05       Impact factor: 7.124

5.  Relationship of hepatic steatosis to adipose tissue distribution in pediatric nonalcoholic fatty liver disease.

Authors:  Mark H Fishbein; Chris Mogren; Theodore Gleason; W Ross Stevens
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-01       Impact factor: 2.839

6.  Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe.

Authors:  Robert P Myers; Gilles Pomier-Layrargues; Richard Kirsch; Aaron Pollett; Melanie Beaton; Mark Levstik; Andres Duarte-Rojo; David Wong; Pam Crotty; Magdy Elkashab
Journal:  J Hepatol       Date:  2011-10-23       Impact factor: 25.083

7.  Steatohepatitis in obese children: a cause of chronic liver dysfunction.

Authors:  J R Moran; F K Ghishan; S A Halter; H L Greene
Journal:  Am J Gastroenterol       Date:  1983-06       Impact factor: 10.864

8.  Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer; Reena Deutsch; Jeffrey B Rauch; Cynthia Behling; Robert Newbury; Joel E Lavine
Journal:  J Pediatr       Date:  2003-10       Impact factor: 4.406

9.  The risk factors for ultrasound-diagnosed non-alcoholic fatty liver disease among adolescents.

Authors:  Chen-Chung Fu; Ming-Chen Chen; Yin-Ming Li; Tso-Tsai Liu; Li-Yu Wang
Journal:  Ann Acad Med Singapore       Date:  2009-01       Impact factor: 2.473

10.  Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004.

Authors:  Abigail Fraser; Matthew P Longnecker; Debbie A Lawlor
Journal:  Gastroenterology       Date:  2007-09-02       Impact factor: 22.682

View more
  8 in total

Review 1.  What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?

Authors:  Giovanni Tarantino; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

2.  What is the appropriate strategy for diagnosing NAFLD using ultrasonography in obese children?

Authors:  Jee Hyun Lee; Su Jin Jeong
Journal:  World J Pediatr       Date:  2017-01-19       Impact factor: 2.764

3.  Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels.

Authors:  Jean P Molleston; Jeffrey B Schwimmer; Katherine P Yates; Karen F Murray; Oscar W Cummings; Joel E Lavine; Elizabeth M Brunt; Ann O Scheimann; Aynur Unalp-Arida
Journal:  J Pediatr       Date:  2013-12-19       Impact factor: 4.406

4.  Accuracy of computer-aided ultrasound as compared with magnetic resonance imaging in the evaluation of nonalcoholic fatty liver disease in obese and eutrophic adolescents.

Authors:  José Hermes Ribas do Nascimento; Ricardo Bernardi Soder; Matias Epifanio; Matteo Baldisserotto
Journal:  Radiol Bras       Date:  2015 Jul-Aug

5.  Cut-Off Values of Visceral Adiposity to Predict NAFLD in Brazilian Obese Adolescents.

Authors:  Ana Paula Grotti Clemente; Bárbara Dal Molin Netto; Aline di Piano Ganen; Lian Tock; Danielle Arisa Caranti; Marco Túlio de Mello; Sergio Tufik; Ana R Dâmaso
Journal:  J Nutr Metab       Date:  2013-12-07

6.  Association of Plasma Retinol Binding Protein-4 (RBP4) and Sonographic Grading of Fatty Liver in Obese Iranian Children.

Authors:  Forough Saki; Zohreh Karamizadeh; Naser Honar; Hossein Moravej; Soheil Ashkani-Esfahani; Mohammad Hossein Namvar Shooshtarian
Journal:  Hepat Mon       Date:  2012-12-30       Impact factor: 0.660

7.  Metabolic syndrome, insulin resistance and Fatty liver in obese Iranian children.

Authors:  Forough Saki; Zohreh Karamizadeh
Journal:  Iran Red Crescent Med J       Date:  2014-05-05       Impact factor: 0.611

Review 8.  Steatosis and steatohepatitis: complex disorders.

Authors:  Kira Bettermann; Tabea Hohensee; Johannes Haybaeck
Journal:  Int J Mol Sci       Date:  2014-06-03       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.